Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials

• Published in: Circulation (New York, N.Y.) Vol. 118; no. 24; pp. 2515 - 2522
• Main Authors: Vergeer, Menno, Bots, Michiel L., van Leuven, Sander I., Basart, Dick C., Sijbrands, Eric J., Evans, Gregory W., Grobbee, Diederick E., Visseren, Frank L., Stalenhoef, Anton F., Stroes, Erik S., Kastelein, John J.P.
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 09.12.2008
• Subjects: Adult; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; Atherosclerosis (general aspects, experimental research); Atherosclerosis - drug therapy; Atorvastatin Calcium; Biological and medical sciences; Blood and lymphatic vessels; Blood Pressure - drug effects; Cardiology. Vascular system; Cholesterol Ester Transfer Proteins - antagonists & inhibitors; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Female; Heptanoic Acids - administration & dosage; Humans; Male; Medical sciences; Middle Aged; Mineralocorticoids; Pyrroles - administration & dosage; Quinolines - administration & dosage; Quinolines - toxicity; Vascular disease; Torcetrapib; Toxicity; drugs; Atherosclerosis; Lipids; Cardiovascular disease; imaging; Cholesterol; Antilipemic agent

Background— Torcetrapib, an inhibitor of cholesteryl ester transfer protein, has been shown to increase the cardiovascular event rate despite conferring a significant high-density lipoprotein cholesterol increase. Using data from the Rating Atherosclerotic Disease Change by Imaging with a New CETP I...